BACKGROUND: Drug-eluting stents (DES) have been introduced successfully in clinical practice to prevent post-angioplasty restenosis. Nevertheless, concerns about the safety of DES still exist. OBJECTIVE: To investigate the vascular pathology and transcriptional responses to sirolimus and paclitaxel in a murine model for restenosis on underlying diseased atherosclerotic arteries. METHODS: Atherosclerotic lesions were induced by placement of a perivascular cuff around the femoral artery of hypercholesterolaemic ApoE*3-Leiden transgenic mice. Two weeks later these cuffs were replaced either by sirolimus- or paclitaxel-eluting cuffs. The vascular pathological effects were evaluated after two additional weeks. RESULTS: Both anti-restenotic compounds significantly inhibited restenotic lesion progression on the atherosclerotic plaques. Vascular histopathological analyses showed that local delivery of sirolimus has no significant adverse effects on vascular disease. Conversely, high dosages of paclitaxel significantly increased apoptosis, internal elastic lamina disruption, and decreased medial and intimal smooth muscle cells and collagen content. Moreover, transcriptional analysis by real-time RT-PCR showed an increased level of pro-apoptotic mRNA transcripts (FAS, BAX, caspase 3) in paclitaxel-treated arteries. CONCLUSIONS: Sirolimus and paclitaxel are effective in preventing restenosis. Sirolimus has no significant effect on arterial disease. In contrast, paclitaxel at high concentration demonstrated adverse vascular pathology and transcriptional responses, suggesting a narrower therapeutic range of this potent drug. Since the use of overlapping stents is becoming more common in DES technology, this factor is important, given that higher dosages of paclitaxel may lead to increased apoptosis in the vessel wall and, consequently, to a more unstable phenotype of the pre-existing atherosclerotic lesion.
BACKGROUND: Drug-eluting stents (DES) have been introduced successfully in clinical practice to prevent post-angioplasty restenosis. Nevertheless, concerns about the safety of DES still exist. OBJECTIVE: To investigate the vascular pathology and transcriptional responses to sirolimus and paclitaxel in a murine model for restenosis on underlying diseased atherosclerotic arteries. METHODS:Atherosclerotic lesions were induced by placement of a perivascular cuff around the femoral artery of hypercholesterolaemic ApoE*3-Leiden transgenic mice. Two weeks later these cuffs were replaced either by sirolimus- or paclitaxel-eluting cuffs. The vascular pathological effects were evaluated after two additional weeks. RESULTS: Both anti-restenotic compounds significantly inhibited restenotic lesion progression on the atherosclerotic plaques. Vascular histopathological analyses showed that local delivery of sirolimus has no significant adverse effects on vascular disease. Conversely, high dosages of paclitaxel significantly increased apoptosis, internal elastic lamina disruption, and decreased medial and intimal smooth muscle cells and collagen content. Moreover, transcriptional analysis by real-time RT-PCR showed an increased level of pro-apoptotic mRNA transcripts (FAS, BAX, caspase 3) in paclitaxel-treated arteries. CONCLUSIONS:Sirolimus and paclitaxel are effective in preventing restenosis. Sirolimus has no significant effect on arterial disease. In contrast, paclitaxel at high concentration demonstrated adverse vascular pathology and transcriptional responses, suggesting a narrower therapeutic range of this potent drug. Since the use of overlapping stents is becoming more common in DES technology, this factor is important, given that higher dosages of paclitaxel may lead to increased apoptosis in the vessel wall and, consequently, to a more unstable phenotype of the pre-existing atherosclerotic lesion.
Authors: P H Quax; M L Lamfers; J H Lardenoye; J M Grimbergen; M R de Vries ; J Slomp; M C de Ruiter ; M M Kockx; J H Verheijen; V W van Hinsbergh Journal: Circulation Date: 2001-01-30 Impact factor: 29.690
Authors: Francesco Saia; Giancarlo Piovaccari; Antonio Manari; Andrea Santarelli; Alberto Benassi; Enrico Aurier; Pietro Sangiorgio; Fabio Tarantino; Giuseppe Geraci; Giuseppe Vecchi; Paolo Guastaroba; Roberto Grilli; Antonio Marzocchi Journal: J Am Coll Cardiol Date: 2006-09-14 Impact factor: 24.094
Authors: A Farb; P F Heller; S Shroff; L Cheng; F D Kolodgie; A J Carter; D S Scott; J Froehlich; R Virmani Journal: Circulation Date: 2001-07-24 Impact factor: 29.690
Authors: J H Lardenoye; D J Delsing; M R de Vries; M M Deckers; H M Princen; L M Havekes; V W van Hinsbergh; J H van Bockel; P H Quax Journal: Circ Res Date: 2000-08-04 Impact factor: 17.367
Authors: T Suzuki; G Kopia; S Hayashi ; L R Bailey; G Llanos; R Wilensky; B D Klugherz; G Papandreou; P Narayan; M B Leon; A C Yeung; F Tio; P S Tsao; R Falotico; A J Carter Journal: Circulation Date: 2001-09-04 Impact factor: 29.690
Authors: Shuzou Tanimoto; Joost Daemen; Keiichi Tsuchida; Héctor M García-García; Peter de Jaegere; Ron T van Domburg; Patrick W Serruys Journal: Catheter Cardiovasc Interv Date: 2007-01 Impact factor: 2.692
Authors: D E Drachman; E R Edelman; P Seifert; A R Groothuis; D A Bornstein; K R Kamath; M Palasis; D Yang; S H Nott; C Rogers Journal: J Am Coll Cardiol Date: 2000-12 Impact factor: 24.094
Authors: A W Heldman; L Cheng; G M Jenkins; P F Heller; D W Kim; M Ware; C Nater; R H Hruban; B Rezai; B S Abella; K E Bunge; J L Kinsella; S J Sollott; E G Lakatta; J A Brinker; W L Hunter; J P Froehlich Journal: Circulation Date: 2001-05-08 Impact factor: 29.690
Authors: Franz X Kleber; Antonia Schulz; Matthias Waliszewski; Telse Hauschild; Michael Böhm; Ulrich Dietz; Bodo Cremers; Bruno Scheller; Yvonne P Clever Journal: Clin Res Cardiol Date: 2014-10-28 Impact factor: 5.460
Authors: Abraham R Tzafriri; Neda Vukmirovic; Vijaya B Kolachalama; Irina Astafieva; Elazer R Edelman Journal: J Control Release Date: 2009-11-17 Impact factor: 9.776